Erratum: Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201

Susana N. Banerjee

Gynaecology Department, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, United Kingdom

Els Van Nieuwenhuysen

Carol Aghajanian

Veronique D'hondt

Institut du Cancer de Montpellier (ICM), Montpellier, France

Bradley J. Monk

Andrew Clamp

Emily Prendergast

Ana Oaknin

Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain

Kari Ring

University of Virginia Health System, Charlottesville, VA

Nicoletta Colombo

Robert W. Holloway

AdventHealth Cancer Institute, Orlando, FL

Manuel Rodrigues

Hye Sook Chon

Moffitt Cancer Center, Tampa, FL

Charlie Gourley

Alessandro D. Santin

Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine

Premal H. Thaker

Washington University School of Medicine, Siteman Cancer Center, St. Louis, MO

Christine Gennigens

Gregg Newman

Erin Salinas

Hagop Youssoufian

Department of Medicine, Brown University Health, Providence, RI

Kathleen N. Moore

Division of Gynecologic Oncology Stephenson Cancer Center University of Oklahoma Oklahoma City Oklahoma USA

Stephanie Lustgarten

David M. O'Malley

GOG Foundation and The Ohio State University and The James Comprehensive Cancer Center, Columbus, OH

Toon Van Gorp

Rachel N. Grisham